By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics said in a regulatory document that revenues for full-year 2011 dropped 63 percent year over year.

In its Form 10-K filed with the US Securities and Exchange Commission today, the Israel-based molecular diagnostics firm said that revenues for 2011 came in at $103,000, down from $279,000 in 2010, due primarily to its former distributor in the US ending sales of Rosetta products in late 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.